Andrew Witty to oversee fast-track scheme for ‘breakthrough’ drugsThe UK has announced a fast-track scheme for breakthrough drugs to reach National Health Service (NHS) patients up to four years earlier than at present, it is being reported on Friday. (APMHE 55447)
Companies threaten legal action against NHS for prescribing Avastin in unlicensed eye indicationBayer and Novartis are threatening legal action to prevent NHS patients with wet age-related macular degeneration (AMD) in England being offered Roche’s Avastin (bevacizumab) instead of Lucentis (ranibizumab), it was widely reported on Wednesday.
Company breaches of UK pharma code rise by 63%Breaches by pharmaceuticals companies of the UK prescription medicines code have risen sharply, the Times said on Monday.
Accelerated approval for AZN’s Calquence for blood cancer in U.S.The Times on Wednesday said the U.S. Food and Drug Administration has granted accelerated approval for AstraZeneca’s Calquence (acalabrutinib), a treatment for adults with a rare type of blood cancer called mantle cell lymphoma, who have received at least one prior therapy (APMHE 55404).
FDA committee backs Indivior’s drug for opioid addictionAn advisory committee at the FDA voted 18 to 1 to recommend approval of Indivior’s RBP-6000, a new treatment for opioid addiction, the FT said on Wednesday.
GSK receives FDA boost for new cancer treatmentThe FT on Thursday reported that GlaxoSmithKline has received approval to fast-track the development of a potentially “transformational” blood cancer treatment, as it doubles down on its search for new blockbuster drugs to offset declining sales of older products.
Merck & Co withdraws bid to extend Keytruda’s lung cancer indication in EuropeThe FT at the weekend said that Merck & Co has withdrawn an application with the European medicines regulator that would have allowed its Keytruda immunotherapy to be used in combination with chemotherapy (APMHE 55367).
GSK chief scientist to leave for advisory role in UK governmentThe FT on Friday says GlaxoSmithKline’s chief scientist is set to leave for a senior job in the UK government, according to two people briefed on the situation.
Mylan shares down after exec named in lawsuitShares in Mylan were down 6.1% after 45 state attorneys general targeted one of the company’s top executives as they moved to expand a lawsuit stemming from a years-long probe into alleged price collusion by generic drugmakers, the FT said on Tuesday.
Sanofi confirms 2017 outlook despite struggling diabetes businessSanofi has confirmed its full-year outlook despite cutting sales guidance for its struggling diabetes franchise, the FT said on Thursday.
Teva shares plunge after poor third quarterTeva shares fell on Thursday after the Israeli company cut its full-year outlook and posted disappointing quarterly results amid a sharp downturn in its U.S. generics business, the FT said on Thursday (APMHE 55441).
Immunology treatments boost revenues at ShireShire delivered a solid increase on profits in the third quarter after better than expected sales of its immunology treatments offset the impact of manufacturing problems with one of its other drugs, the FT said at the weekend.
AbbVie raises guidance after solid Q3AbbVie posted adjusted earnings of $1.41 per share, around 3 cents ahead of expectations, while revenues of $6.96 billion were in line with consensus, the FT said at the weekend.
Novartis to buy France’s Advanced Accelerator ApplicationsThe FT on Monday said Novartis has announced a $3.9 billion deal to buy Advanced Accelerator Applications (AAA), a French company specialising in nuclear medicines used to treat tumours.
AZN takes stake in Mereo as part of deal to sell drugAstraZeneca is taking a stake in Mereo Biopharma as part of a deal to sell the commercial rights to AZD9668, which is being developed as a treatment for a rare genetic disorder that causes lung and liver problems.
Shanghai Fosun to buy Africa-focused TridemChina-based Shanghai Fosun Pharmaceutical has agreed to buy Tridem, an Africa-focused French drug distributor, for up to €63 million euros ($73.1 million), the FT said on Monday.
AI approach could do away with need for placebos in trialsThe Sunday Times reported on Medidata, a company that has developed a machine-learning system that could overhaul the testing of experimental treatments by doing away with the need for placebos in clinical trials for new drugs.
Disappointing results for AstraZeneca’s tralokinumab in asthmaThe FT on Wednesday said AstraZeneca has announced “disappointing” trial results for a therapy it has been developing for severe asthma (APMHE 55410).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.